UK Retail Deal Sparks Early Buying Frenzy in Pharma Stock

Sponsored:

Wednesday, April 23, 2025

A specialty pharmaceutical company based out of Georgia is turning heads already during Tuesday’s premarket hours after the company announced that its hypochlorous acid-based acne products will be sold through a health and beauty retailer and pharmacy chain in the United Kingdom. According to the release, the ‘prominent’ UK pharmacy chain has over 1,200 stores. 

Traders wasted absolutely no time buying up shares of Sonoma Pharmaceuticals Inc. (Nasdaq:SNOA), with shares of the micro cap currently bid up at $4.43/share (90.13% implied open for sellers) at the time of writing. This should be an exciting session for this stock, building on yesterday’s +4.95% rally!

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

Sponsored: